Literature DB >> 16396796

Toxic epidermal necrolysis: analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients.

Kyoung Jin Kim1, Deuk Pyo Lee, Ho Seok Suh, Mi Woo Lee, Jee Ho Choi, Kee Chan Moon, Jai Kyoung Koh.   

Abstract

Toxic epidermal necrolysis (TEN) is a rare, life-threatening, drug-induced cutaneous reaction. We herein report our experience regarding causes, clinical course, treatment and sequelae of TEN in Korean patients. In addition, we used the SCORTEN, a severity-of-illness score for TEN, to compare the predicted and actual mortality rates, and to evaluate the efficacy of treatment modalities. A retrospective study of 38 patients with TEN during a 13-year period (1990-2003) at the Asan Medical Center was performed. The mean involved body surface area was 49+/-17%. All except three cases were associated with medications, most commonly antibiotics, followed by non-steroidal anti-inflammatory drugs, acetaminophen and herbal remedies. Fourteen patients had a history of current infection, including upper respiratory infection, pneumonia and herpes simplex infection. The mean time from initial drug administration to the onset of TEN was 9.8+/-5.7 days. Twenty-one patients were treated with systemic corticosteroids. Fourteen received high dose intravenous immunoglobulin therapy. The actual mortality rate was 23.7% (9/38), not significantly different from the SCORTEN-predicted rate (25.5%, 9.699/38). Also based on SCORTEN, treatment with high dose intravenous immunoglobulin showed a trend to lower actual mortality than predicted mortality (standardized mortality ratio (SMR) = 0.425; 95% CI, 0.011-2.368), whereas corticosteroid therapy showed no such difference (SMR = 1.004; 95% CI, 0.369-2.187).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16396796     DOI: 10.1080/00015550510038232

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  11 in total

1.  Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality.

Authors:  Jean-Claude Roujeau; Sylvie Bastuji-Garin
Journal:  Ther Adv Drug Saf       Date:  2011-06

2.  Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.

Authors:  Megan H Noe; Misha Rosenbach; Rebecca A Hubbard; Arash Mostaghimi; Adela R Cardones; Jennifer K Chen; Jonathan Cotliar; Mark D P Davis; Arturo Dominguez; Lindy P Fox; Lauren C Hughey; Benjamin H Kaffenberger; Daniela Kroshinsky; Bernice Y Kwong; Daniel D Miller; Amy Musiek; Alex G Ortega-Loayza; Victoria R Sharon; Kanade Shinkai; Erika M Summers; Karolyn A Wanat; David A Wetter; Scott Worswick; David J Margolis; Joel M Gelfand; Robert G Micheletti
Journal:  JAMA Dermatol       Date:  2019-04-01       Impact factor: 10.282

3.  Review of intravenous immunoglobulin in the treatment of stevens-johnson syndrome and toxic epidermal necrolysis.

Authors:  Saira B Momin
Journal:  J Clin Aesthet Dermatol       Date:  2009-02

4.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

5.  Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database.

Authors:  Bénédicte Lebrun-Vignes; Claire Guy; Marie-Josèphe Jean-Pastor; Valérie Gras-Champel; Marie Zenut
Journal:  Br J Clin Pharmacol       Date:  2017-11-10       Impact factor: 4.335

Review 6.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

7.  The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis.

Authors:  Liang-Ping Ye; Cheng Zhang; Qi-Xing Zhu
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

8.  Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients.

Authors:  Carlos Gustavo Wambier; Thaís Angélica Hoekstra; Sarah Perillo de Farias Wambier; Roberto Bueno Filho; Fernando Crivelenti Vilar; Renato Soriani Paschoal; Ana Maria Roselino; Marco Andrey Cipriani Frade; Norma Tiraboschi Foss
Journal:  An Bras Dermatol       Date:  2019 Jan-Feb       Impact factor: 1.896

9.  Toxic epidermal necrolysis induced by lamotrigine treatment in a child.

Authors:  Youngsuk Yi; Jeong Ho Lee; Eun Sook Suh
Journal:  Korean J Pediatr       Date:  2014-03-31

10.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Acetaminophen Use during Viral Infections.

Authors:  Ga-Young Ban; Seun-Joo Ahn; Hye-Soo Yoo; Hae-Sim Park; Young-Min Ye
Journal:  Immune Netw       Date:  2016-08-23       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.